Oncology firm Elekta has obtained regulatory approval for its proposed acquisition of radiation therapy firm Nucletron for 365 million euros ($522.1 million U.S.) in cash.
Elekta plans to add Nucletron's brachytherapy products as a fourth business segment, joining Elekta's current oncology, neuroscience, and software units. The closing of the transaction could occur in the coming days.
Elekta estimated that Nucletron will add approximately 1,000 new customers to its customer base of more than 5,000 clients.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
